InterCure upgraded by Canaccord Genuity with a new price target
$INCR
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/18/2022 | $13.00 | Speculative Buy → Buy | Canaccord Genuity |
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YORK and HERZLIYA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company"), today announced its financial and operating results for the first half of 2025. Al
Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as Trump administration confirms it is exploring cannabis rescheduling, creating unprecedented potential opportunities for international operators like InterCure InterCure encouraged by recent regulatory momentum and positioned to capitalize on evolving U.S. cannabis landscape NEW YORK & HERZLIYA, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced the strategic acquisition of Botanico Ltd., also
2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility. InterCure received NIS 62 million until December 31, 2024 (to date, NIS 82 million) as partial advanced payments from the Israeli authorities and expects to receive additional substantial payments.Revenues in 2024 reached NIS 239 million, alongside an Adjusted EBITDA[1] of NIS 24 million (approximately 10% of revenues).InterCure announced expansion of its strategic partnership with Cookies™ to Germany and expec
Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00
6-K - Intercure Ltd. (0001857030) (Filer)
6-K - Intercure Ltd. (0001857030) (Filer)
6-K - Intercure Ltd. (0001857030) (Filer)
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9
Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High
Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results
SC 13G - Intercure Ltd. (0001857030) (Subject)